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dose rate brachytherapy with Ir192 source used to deliver 10 
Gy/1fr at 1 cm radius from the center of source. PTBD tube 
was replaced by 10 mm, non sheathed self expandable 
metallic modified Giantruco Z stent. In EBRT group, stenting, 
followed by EBRT(dose of 45Gy/25fr/ 5 weeks) by conformal 
technique to primary tumour and stent area. All the patients 
were given single agent 5-Fluorouracil chemotherapy 370 
mg/m2 Day1-5 at 4 weekly for 6 cycles. 
 
Results: Palliation of jaundice and pruritus was achieved in 
all. The median overall survival in ILBT and EBRT group was 8 
and 9 months with the stent patency 7 and 8 months and 
overall survival at 1 year was 21% and 23%. Gastric outlet 
obstruction was 29% in ILBT group and 19% in EBRT 
group(p=ns), while distant failure rate were 60 % & 55%. No 
ILBT related morbidity was observed. 
 
Conclusion: PTBD is safe, well tolerated and effective in 
palliation of Jaundice. Intraluminal Brachytherapy (ILBT) 
appears to prolong stent patency The addition of EBRT to 
ILBT does not show any advantage in terms of stent patency 
and overall survival. 
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Purpose or Objective: In a retrospective study of 100 
consecutive patients treated with Ru-106 eye plaques for 
uveal melanoma from 2005 to 2008 at our clinic, we aimed to 
investigate the correlation between the dose to the optic 
nerve and optic nerve damage; the dose to the macula and 
macular damage; and the minimum dose to the tumour and 
tumour control.  
 
Material and Methods: Pre-treatment fundus images were 
imported into Plaque Simulator TM and the tumour was 
retrospectively contoured by an ophthalmologist. The plaque 
position was determined from the radiation scar on post-
treatment images. 3D dosimetric data was calculated. The 
point doses to the optic nerve and macula and minimum dose 
to the tumour were estimated. TCP, and damage to the optic 
nerve and macula, were determined from the patients’ 
notes. The correlations between optic nerve damage, 
macular damage and TCP with dose, dose rate, gender, and 
plaque type was investigated using univariate and 
multivariate analyses. 
 
Results: 16 % of the patients developed optic nerve damage. 
Only optic nerve dose was correlated with damage to the 
optic nerve (p=0,000063) in univariate analysis.  
51% of the patients had macular damage. Only macular dose 
was correlated with damage (p=0,00049) in univariate 
analysis.  
32 % of the patients did not achieve tumour control. TCP was 
correlated with minimum tumour dose and gender in 
univariate analysis. Patients with minimum doses > 80 Gy had 
100% TCP.For 80% of the patients with tumour recurrence, 
the plaque did not geometrically overlap the tumour.  
Dose response curves were drawn for optic nerve damage, 
macular damage and TCP. Such curves could not be found in 
the literature so no comparison was possible. Previously 
published values for TCP are similar to, or higher than, the 
one found in the present material. However, the papers 
citing higher values have selected patients with smaller 
tumours, which tend to have higher values of TCP. We 
emphasise that the number of patients is quite small and that 
a study of a large patient cohort is planned.  
 
Conclusion: Tumour control only failed in patients who 
received less than the prescription dose. The use of image 
guided planning software (such as Plaque Simulator TM) may 
aid in optimizing tumour control in the future. The present 
analysis presents the first reported dose response curves for 
damage to the optic nerve and macula. This information may 
be useful in delivering the optimal treatments in future.  
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Purpose or Objective: Treatment of uveal melanoma by 
means of brachytherapy using 106Ru eye plaques achieves 
very good tumor control while keeping morbidity at an 
acceptable level. However, a deeper understanding of the 
underlying dose-response relationship is still missing not least 
because of the lack of appropriate software packages for 3D 
treatment planning and volumetric dose assessment. This 
motivated the in-house development of software modules to 
calculate the dose distributions in critical, ophthalmologic 
structures as well as tumor for an eye model. 
 
Material and Methods: A resizable 3D model of an eye was 
created in Sidefx Houdini, consisting of lens, ciliary body and 
optic nerve as well as macula, retina and sclera. A dome-
shaped tumor model can be added with apex height and basal 
diameter as adjustable parameters. The position of the 
tumor model can be fixed by reference to the distance 
between tumor and macula and tumor and optical nerve. 
Alternatively fundus images can be incorporated into the 3D 
model in order to account for the individual tumor shape. A 
specially designed algorithm projects the images onto the 
virtual eye model and converts them to volumetric data. 
Different types of BEBIG eye plaques (CCA, CCB and COB) can 
be positioned within the computer model. Corresponding 
dosimetric lookup tables were generated from MC simulations 
using MCNP6. Superposition onto the 3D eye model enables 
the calculation of doses and dose volume parameters for the 
tumor and adjacent healthy tissue. Finally, dosimetric safety 
margins have been obtained by performing film 
measurements and can be included in order to determine 
dosimetric uncertainties. 
 
Results: The software modules can calculate full 3D dose 
distributions with a cubic dose grid of 200 µm in < 5 s (and < 
1 s with GPU). The 3D eye model can be adjusted on the 
basis of simple geometric measures such as the measured size 
of the eye as well the distances between tumor, macula and 
optic nerve and thereby be used for individual treatment 
planning, i.e. the selection and positioning of the type of 
plaque. The registered fundus projection can be used to 
guide the tumor delineation. Dose-volume metrics can be 
generated for all structures of the individualized model which 
in turn can be used for assessing dose-response relationships 
for the target volume and organs-at-risk. The dosimetric 
uncertainty assessment provides information on safety 
margins. Local agreement between MC and film was better 
than 6 % for the first 7 mm. 
 
Conclusion: In this study we presented novel software 
modules for treatment planning in 106Ru eye plaque 
brachytherapy of uveal melanomas. It is aimed to be used in 
daily treatment planning as well as for performing pro- and 
retrospective studies to provide further information on dose-
response relationships and prognostic values for treatment 
morbidity and local control. Future works involves the 
registration of pre- and/or post-application MR images as 
